In focus · trending topic

ADHD

53 stories · following the connections

Neos Therapeutics to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017

By Nasdaq OMXAug 2, 2017, 11:30 AM UTC

Neos Therapeutics Announces Proposed Offering of Common Stock

By Nasdaq OMXJun 26, 2017, 8:02 PM UTC

Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old

By Nasdaq OMXJun 20, 2017, 1:47 AM UTC

Neos Therapeutics to Present at the JMP Securities 2017 Life Sciences Conference

By Nasdaq OMXJun 14, 2017, 11:30 AM UTC

Neos Therapeutics to Present at Jefferies 2017 Global Healthcare Conference

By Nasdaq OMXMay 30, 2017, 11:34 AM UTC

Neos Therapeutics to Present at Jefferies 2017 Global Healthcare Conference

By Nasdaq OMXMay 30, 2017, 11:33 AM UTC

Neos Therapeutics to Present at Jefferies 2017 Global Healthcare Conference

By Nasdaq OMXMay 30, 2017, 11:33 AM UTC

Neos Therapeutics to Present at Jefferies 2017 Global Healthcare Conference

By Nasdaq OMXMay 30, 2017, 11:33 AM UTC